GMAB Stock Analysis: Buy, Sell, or Hold?
GMAB - Genmab A/S ADS
$25.83
0.01 (0.04%)
▲
5d:
+0.58%
30d:
-12.26%
90d:
-22.71%
BUY
HIGH Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When GMAB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: GMAB trading at deep discount. Market pricing in -8.8% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: GMAB trading at deep discount. Market pricing in -8.8% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$66.47
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$41.28
37.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 19.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GMAB is currently trading at $25.83, which is considered slightly low relative to its 30-day fair value range of $25.88 to $28.77. From a valuation perspective, the stock is trading at a discount (Forward PE: 14.4) compared to its historical average (19.1). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GMAB is in a uptrend. Immediate support is located at $24.95, while resistance sits at $26.79.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $37.65 (+45.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, GMAB is in a uptrend. Immediate support is located at $24.95, while resistance sits at $26.79.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $37.65 (+45.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$25.88 -
$28.77
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
79.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 45.8% below Wall St target ($37.65)
Fair Price Analysis
30-Day Fair Range
$25.88 -
$28.77
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$24.95
Resistance Level
$26.79
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
14.45
Wall Street Target
$37.65
(+45.8%)
Revenue Growth (YoY)
3.0%
Earnings Growth (YoY)
-94.4%
Profit Margin
25.9%
Valuation Discount vs History
-8.8% cheaper
PE vs Historical
14.5 vs 19.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.8%
(market-implied from PE analysis)
1-Year Target
$23.55
(-9%)
2-Year Target
$21.48
(-17%)
3-Year Target
$19.59
(-24%)
3-Yr Target (if PE normalizes)
(PE: 14→19)
$25.89
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 63.5%)
$135.11
(+423%)
Base:
(SPY PE: 14.4, Growth: 63.5%)
$87.14
(+238%)
Bear:
(PE: 12.3, Growth: 63.5%)
$74.07
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (14x PE) as earnings recover.
Trailing PE: 16.30 | Current EPS (TTM): $1.54
Bull Case
$32.04
(+25%)
Analyst growth 16.1%, PE expands to 17.9
Base Case
$29.13
(+13%)
Market implied 16.1%, PE stable at 16.3
Bear Case
$17.07
(-34%)
Severe decline -20.0%, PE contracts to 13.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 14.4 to 19.1
Stabilization Target:
$34.14
(+32.2%)
PE Expansion Potential:
+32.2%
Share & Embed Analysis
Last updated: March 30, 2026 5:00 PM ET
Data refreshes hourly during market hours. Next update: 6:00 PM
Data refreshes hourly during market hours. Next update: 6:00 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GMAB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 48 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 67 BUY |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$111 | 57 HOLD |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 57 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 45 HOLD |
